Guidelines for Fracture Risk Assessment and Management of Osteoporosis in Postmenopausal Women and Men Above the Age of 50 in Qatar

Overview

Journal Arch Osteoporos

Publisher Springer

Date 2024 May 2

PMID 38698101

Authors

Fiaz Alam

Omar Alsaed

Nabeel Abdulla

Ibrahim Abdulmomen

Abdo Lutf

Samar Al Emadi

Affiliations

Soon will be listed here.

Abstract

Purpose: Osteoporosis and related fragility fractures are a growing public health issue with an impact on individuals and the healthcare system. We aimed to present guidelines providing unified guidance to all healthcare professionals in Qatar regarding the management of osteoporosis.

Methods: The Qatar Osteoporosis Association formulated guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men above the age of 50. A panel of six local rheumatologists who are experts in the field of osteoporosis met together and conducted an extensive review of published articles and local and international guidelines to formulate guidance for the screening and management of postmenopausal women and men older than 50 years in Qatar.

Results: The guidelines emphasize the use of the age-dependent hybrid model of the Qatar fracture risk assessment tool for screening osteoporosis and risk categorization. The guidelines include screening, risk stratification, investigations, treatment, and monitoring of patients with osteoporosis. The use of a dual-energy X-ray absorptiometry scan without any risk factors is discouraged. Treatment options are recommended based on risk stratification.

Conclusion: Guidance is provided to all physicians across the country who are involved in the care of patients with osteoporosis and fragility fractures.

References

Ciullini L, Pennica A, Argento G, Novarini D, Teti E, Pugliese G . Trabecular bone score (TBS) is associated with sub-clinical vertebral fractures in HIV-infected patients. J Bone Miner Metab. 2017; 36(1):111-118. DOI: 10.1007/s00774-017-0819-6. View

Silverman S, Calderon A . The utility and limitations of FRAX: A US perspective. Curr Osteoporos Rep. 2010; 8(4):192-7. PMC: 2947011. DOI: 10.1007/s11914-010-0032-1. View

Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle S, Grauer A . Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. 2018; 30(1):79-92. PMC: 6332293. DOI: 10.1007/s00198-018-4732-1. View

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

Saag K, Zanchetta J, Devogelaer J, Adler R, Eastell R, See K . Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60(11):3346-55. DOI: 10.1002/art.24879. View

Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H . Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282(7):637-45. DOI: 10.1001/jama.282.7.637. View

Lewiecki E, Dinavahi R, Lazaretti-Castro M, Ebeling P, Adachi J, Miyauchi A . One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2018; 34(3):419-428. DOI: 10.1002/jbmr.3622. View

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020; 26(Suppl 1):1-46. DOI: 10.4158/GL-2020-0524SUPPL. View

Cummings S, Ferrari S, Eastell R, Gilchrist N, Jensen J, McClung M . Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2017; 33(2):190-198. DOI: 10.1002/jbmr.3337. View

10.

Bone H, Bolognese M, Yuen C, Kendler D, Miller P, Yang Y . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011; 96(4):972-80. DOI: 10.1210/jc.2010-1502. View

11.

Turner D, Fong Soe Khioe R, Shepstone L, Lenaghan E, Cooper C, Gittoes N . The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. J Bone Miner Res. 2018; 33(5):845-851. PMC: 5993187. DOI: 10.1002/jbmr.3381. View

12.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

13.

Alsaed O, Abdulla N, Lutf A, Abdulmomen I, Alam F, Alemadi S . Incidence rate of osteoporotic hip fracture in Qatar. Arch Osteoporos. 2021; 16(1):150. PMC: 8492571. DOI: 10.1007/s11657-021-01010-8. View

14.

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

15.

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

16.

Johansson H, Siggeirsdottir K, Harvey N, Oden A, Gudnason V, McCloskey E . Imminent risk of fracture after fracture. Osteoporos Int. 2016; 28(3):775-780. PMC: 5338733. DOI: 10.1007/s00198-016-3868-0. View

17.

Johansson H, Kanis J, Oden A, Leslie W, Fujiwara S, Gluer C . Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int. 2014; 95(5):428-35. PMC: 4361897. DOI: 10.1007/s00223-014-9911-2. View

18.

Nayak S, Greenspan S . A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk. Osteoporos Int. 2019; 30(4):705-720. PMC: 6499675. DOI: 10.1007/s00198-018-4791-3. View

19.

Paggiosi M, Peel N, Eastell R . The impact of glucocorticoid therapy on trabecular bone score in older women. Osteoporos Int. 2015; 26(6):1773-80. DOI: 10.1007/s00198-015-3078-1. View

20.

Ulivieri F, Silva B, Sardanelli F, Hans D, Bilezikian J, Caudarella R . Utility of the trabecular bone score (TBS) in secondary osteoporosis. Endocrine. 2014; 47(2):435-48. DOI: 10.1007/s12020-014-0280-4. View